Letter to the Editor

US Food and Drug Administration. Recall—firm press release. Baxter to proceed with recall of remaining heparin sodium vial products. http://www.fda.gov/oc/po/firmrecalls/baxter02_08.htm. Accessed April 24, 2008.

US Food and Drug Administration. Baxter issues urgent nationwide voluntary recall of heparin 1,000 units/ml 10 and 30 ml multi-dose vials. http://www.fda.gov/oc/po/firmrecalls/baxter01_08.html. Accessed April 24, 2008.

Centers for Disease Control and Prevention. Acute allergic-type reactions among patients undergoing hemodialysis—multiple states, 2007–2008. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm57e201a1.htm?s_cid=mm57e201a1_e. Accessed February 11, 2008.

Guerrini M. , Beccati D. , Shriver Z. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol. 2008; DOI: 10.1038/nbt1407. http://www.nature.com/nbt/journal/vaop/ncurrent/full/nbt1407.html. Accessed May 2, 2008.

Kishimoto T.K. , Viswanathan K. , Ganguly T. Contaminated heparin associated with adverse clinical events and activation of the contact system. New Engl J Med. 2008; DOI: 10.1056/NEJMoa0803200. http://content.nejm.org/cgi/content/full/NEJMoa0803200. Accessed May 2, 2008.